2,553 Amgen Inc. $AMGN Shares Sold by Kelleher Financial Advisors

Kelleher Financial Advisors reduced its stake in shares of Amgen Inc. (NASDAQ:AMGN) by 48.6% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 2,703 shares of the medical research company’s stock after selling 2,553 shares during the quarter. Kelleher Financial Advisors’ holdings in Amgen were worth $1,140,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds also recently added to or reduced their stakes in the stock. State Street Corp grew its position in shares of Amgen by 38.2% in the second quarter. State Street Corp now owns 42,205,243 shares of the medical research company’s stock valued at $15,283,363,000 after purchasing an additional 11,656,755 shares during the last quarter. MW Advisory LLC purchased a new position in shares of Amgen during the 2nd quarter worth approximately $1,054,000. Baird Financial Group Inc. raised its position in shares of Amgen by 1.6% during the 2nd quarter. Baird Financial Group Inc. now owns 339,825 shares of the medical research company’s stock worth $123,057,000 after purchasing an additional 5,496 shares during the last quarter. MassMutual Private Wealth & Trust FSB raised its position in shares of Amgen by 105.8% during the 3rd quarter. MassMutual Private Wealth & Trust FSB now owns 13,514 shares of the medical research company’s stock worth $5,696,000 after purchasing an additional 6,947 shares during the last quarter. Finally, Nilsine Partners LLC acquired a new position in shares of Amgen during the 2nd quarter worth approximately $3,329,000. 76.50% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In related news, SVP Rachna Khosla sold 2,000 shares of the stock in a transaction dated Tuesday, August 11th. The stock was sold at an average price of $412.57, for a total transaction of $825,140.00. Following the transaction, the senior vice president directly owned 6,404 shares in the company, valued at approximately $2,642,098.28. This represents a 23.80% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Insiders own 0.85% of the company’s stock.

More Amgen News

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Amgen reported adjusted earnings of $6.45 per share and revenue of $10.37 billion, topping analyst estimates; revenue increased 8.5% year over year. The company also raised its 2026 outlook to $38.9 billion–$39.7 billion in revenue and $18.34–$19.28 in GAAP EPS. Amgen third-quarter financial results
• Positive Sentiment: Growth in medicines including Repatha and IMDELLTRA helped offset pressure elsewhere. Amgen also highlighted pipeline progress, including IMDELLTRA and potential longer-term growth from its obesity candidate MariTide. Amgen raises 2026 outlook
• Positive Sentiment: Several firms raised their targets, including UBS and Scotiabank to $530 and Goldman Sachs to $536, with buy or outperform ratings. These revisions suggest some analysts see further upside after the results. Analyst views and revised targets
• Neutral Sentiment: Analyst opinion remains divided: some target increases still leave estimates below the prevailing share price, and MariTide data is a future catalyst rather than a near-term result. RBC Capital adjusts Amgen target
• Negative Sentiment: Investors remain concerned about steep declines in Prolia and Xgeva as biosimilar competition weighs on sales. That erosion may limit how much growth from newer products translates into future results. Sales and biosimilar concerns

Amgen Stock Up 3.7%

Shares of NASDAQ AMGN opened at $478.48 on Thursday. The firm has a market cap of $258.68 billion, a P/E ratio of 27.75, a price-to-earnings-growth ratio of 3.38 and a beta of 0.43. The company has a debt-to-equity ratio of 4.44, a quick ratio of 1.13 and a current ratio of 1.37. Amgen Inc. has a 1 year low of $302.13 and a 1 year high of $482.48. The firm’s 50 day moving average price is $421.56 and its 200 day moving average price is $376.90.

Amgen (NASDAQ:AMGN) last issued its quarterly earnings results on Tuesday, November 3rd. The medical research company reported $6.45 earnings per share for the quarter, beating the consensus estimate of $5.79 by $0.66. Amgen had a return on equity of 128.15% and a net margin of 24.14%. The company had revenue of $10.37 billion during the quarter, compared to the consensus estimate of $10.07 billion. During the same period in the previous year, the firm posted $5.64 EPS. Amgen’s revenue was up 8.5% on a year-over-year basis. As a group, sell-side analysts anticipate that Amgen Inc. will post 22.96 earnings per share for the current year.

Amgen Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, December 11th. Investors of record on Friday, November 20th will be paid a $2.52 dividend. This represents a $10.08 annualized dividend and a yield of 2.1%. The ex-dividend date is Friday, November 20th. Amgen’s dividend payout ratio is presently 62.65%.

Analyst Ratings Changes

A number of equities research analysts recently issued reports on AMGN shares. HSBC lowered Amgen from a “buy” rating to a “hold” rating and reduced their target price for the company from $445.00 to $425.00 in a research note on Thursday, September 10th. Morgan Stanley boosted their price target on Amgen from $359.00 to $410.00 and gave the stock an “equal weight” rating in a report on Wednesday. Mizuho upped their price objective on Amgen from $303.00 to $352.00 and gave the company a “neutral” rating in a research report on Tuesday, August 18th. Robert W. Baird increased their price objective on Amgen from $215.00 to $230.00 and gave the company an “underperform” rating in a research note on Wednesday, August 5th. Finally, The Goldman Sachs Group lifted their price objective on Amgen from $481.00 to $536.00 and gave the stock a “buy” rating in a research report on Wednesday. One research analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating, seventeen have given a Hold rating and three have given a Sell rating to the stock. According to MarketBeat, Amgen presently has a consensus rating of “Hold” and an average target price of $413.38.

Amgen Company Profile

Amgen Inc is a biotechnology company that discovers, develops, manufactures and delivers medicines for serious illnesses. Its research focuses on areas including oncology, cardiovascular disease, inflammation, bone health, nephrology and neuroscience.

The company’s products include biologic and specialty medicines such as Enbrel for inflammatory diseases, Prolia and Evenity for osteoporosis, Xgeva for skeletal-related complications, Repatha for cardiovascular risk reduction, Otezla for inflammatory conditions, Tezspire for severe asthma, Blincyto for certain blood cancers, and Lumakras for specific cancers.

Founded in 1980, Amgen is headquartered in Thousand Oaks, California.